DCM
BMRN icon

Delpha Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Delpha Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-379
Closed -$34K – 256
2017
Q4 		$34K Buy
+379
New +$33K 0.04% 488

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Delpha Capital Management's BMRN Position: Q1 2018 in Review

Delpha Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 379 shares — an estimated $34K sold.

Delpha Capital Management first reported a position in BMRN in Q4 2017 and held it in 1 quarter. The position peaked at $34K in Q4 2017. 430 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

  • Delpha Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 379 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $34K.
  • Delpha Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's BioMarin Pharmaceuticals position peaked at $34K in Q4 2017.
  • 430 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.